<DOC>
	<DOCNO>NCT00655551</DOCNO>
	<brief_summary>The purpose trial evaluate safety intravenous ( iv ) lacosamide deliver single dose follow 6.5 day oral lacosamide treatment subject partial-onset seizure .</brief_summary>
	<brief_title>Safety Intravenous Lacosamide Dose Followed Twice Daily Oral Lacosamide Subjects With Partial-onset Seizures</brief_title>
	<detailed_description>This multicenter , open-label trial examine safety tolerability rapid initiation adjunctive lacosamide via single intravenous load dose follow oral maintenance treatment subject 16 - 60 year age partial-onset seizure . Three consecutive 25-subject cohort give progressively increase dose lacosamide ( 200 , 300 , 400 mg ) administer single 15-minute intravenous ( iv ) load dose follow equivalent daily dose administer orally twice daily 6.5 day first oral dose 12 hour iv dose . A fourth cohort 25 subject repeat 300 mg dose provide safety data total 50 subject high well-tolerated dose .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Diagnosis epilepsy simple partial seizure and/or complex partial seizure Stable dose regimen 1 2 market antiepileptic drug ( ) ( AED ( ) ) 28 day prior screen duration trial Acceptable candidate venipuncture intravenous ( iv ) infusion At least 1 partial seizure motor component per 90 day Maximum allow seizure frequency 28 day prior screen 40 partial seizure type Previous use lacosamide History primary generalize seizure History status epilepticus within last 12 month History cluster seizure 8 week period prior screen Nonepileptic event , include psychogenic seizure could confuse seizure Use neuroleptic , monoamine oxidase ( MAO ) inhibitor , barbiturate , narcotic analgesic within 28 day prior screen Received rescue benzodiazepine 28 day prior screen Concomitant treatment felbamate previous felbamate therapy within last 6 month Prior concomitant vigabatrin use</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>seizure</keyword>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>intravenous</keyword>
</DOC>